The present invention belongs to the technical field of pharmaceuticals. Disclosed are a bifunctional anti-platelet aggregation medicament represented by formula (I) and its uses for preventing and treating arterial thrombotic diseases. The medicament of the present invention has P2Y12 receptor-antagonist activity and phosphodiesterase-inhibiting activity at the same time. The anti-platelet mechanism of the medicament is provided by the experimental results of anti-platelet aggregation activity in vivo and in vitro. The structure and anti-platelet mechanism of the medicament are different from known anti-platelet medicaments Aspirin, Clopidogrel, Prasugrel, Cilostazol and platelet fibrinogen receptor antagonist. The medicament of the present invention shows good inhibiting effects on platelet aggregation induced by many kinds of agonists. The experimental results of the arterial thrombotic model of mice in vivo shows that the medicament has excellent anti-thrombus activity similar to Clopidogrel without any obvious side-effect of bleeding. The medicament of the present invention can be used as anti-thrombus medicines for treating arterial thrombotic diseases such as coronary heart disease, stroke, and so on. Said formula (I) is as follows.La présente invention concerne le domaine de la technologie pharmaceutique. Linvention concerne un médicament antiagrégant plaquettaire bifonctionnel représenté par la formule (I) et ses utilisations pour prévenir et traiter les maladies thrombotiques artérielles. Le médicament de la présente invention a une activité dantagonisation du récepteur P2Y12 et une activité simultanée dinhibition de la phosphodiestérase. Le mécanisme antiplaquettaire du médicament est fourni par les résultats expérimentaux de lactivité antiagrégation plaquettaire in vivo et in vitro. La structure et le mécanisme antiplaquettaire du médicament sont différents des médicaments antiplaquettaires connus Aspirine, Clopidogrel, Prasugrel, Cilostazol et dun antag
